LB Pharmaceuticals Inc
lbpharma.usWhat Do They Do?
Develops a medicine for schizophrenia and mood disorders, for people with neuropsychiatric conditions.
10-K for FY2025, filed Mar 26, 2026We are a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders…View ↗
Our lead product candidate, LB‑102, is a Phase 3 oral small molecule in development for the treatment of schizophrenia. LB-102 is designed…View ↗
In addition to our clinical development program in schizophrenia, we plan to leverage our expertise in neuropsychiatry and the unique…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$51.6MView ↗
- ▲ +959% (Loss)
- vs −$4.9M in Q2 FY2025
-
Sep 3, 2026
Named Joseph Miller chief financial officer
Joseph Miller was appointed CFO, effective September 2, 2026.
Sources
8-K, filed Sep 3, 2026
On September 3, 2026, LB Pharmaceuticals Inc (the “Company”) announced that Joseph M. Miller has been appointed to serve as the Company’s…View ↗
Who Do They Compete With?
Competes with HLS Therapeutics, AstraZeneca, Otsuka Pharmaceutical, Janssen Pharmaceuticals, Eli Lilly &, Sumitomo Pharma America, AbbVie, Vanda Pharmaceuticals, Teva Pharmaceutical Industries, Alkermes, Bristol-Myers Squibb, Alto Neuroscience, Minerva Neurosciences, MapLight Therapeutics, Neurocrine Biosciences, Reviva Pharmaceuticals Holdings, Acadia Pharmaceuticals, NRx Pharmaceuticals, Xenon Pharmaceuticals, and Axsome Therapeutics
10-K for FY2025, filed Mar 26, 2026Patients with schizophrenia have historically been treated with a variety of antipsychotic drugs and, accordingly, we believe LB-102, if…View ↗
Loading...
